Evidence map›Paper›PMID 37725229›Full record

Observational studyAmerican journal of clinical dermatology2024

AtopyReg

Luca Stingeni, Andrea Chiricozzi, Piergiacomo Calzavara-Pinton, Maddalena Napolitano, Ketty Peris, Donatella Schena, Cataldo Patruno, Mariateresa Rossi, Caterina Foti, Maria C Fargnoli and 17 more

Erratum issuedAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in American journal of clinical dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Luca StingeniDermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. luca.stingeni@unipg.it.ORCID http://orcid.org/0000-0001-7919-8141
Andrea ChiricozziUOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Piergiacomo Calzavara-PintonDepartment of Dermatology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Maddalena NapolitanoSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Ketty PerisUOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Donatella SchenaSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Cataldo PatrunoSection of Dermatology, Health Sciences Department, Magna Graecia University, Catanzaro, Italy.
Mariateresa RossiDepartment of Dermatology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Caterina FotiDepartment of Emergency and Organ Transplantation, Allergology and Clinical Immunology, University of Bari, Bari, Italy.
Maria C FargnoliDermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Monica CorazzaSection of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Silvia M FerrucciDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Paolo D PigattoDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Marco RomanelliDermatology Unit, University of Pisa, Pisa, Italy.
Gabriella FabbrociniSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Giampiero GirolomoniSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Maria PassanteSection of Dermatology, Health Sciences Department, Magna Graecia University, Catanzaro, Italy.
Paolo RomitaDepartment of Emergency and Organ Transplantation, Allergology and Clinical Immunology, University of Bari, Bari, Italy.
Maria EspositoDermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Natale SchettiniSection of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Angelo V MarzanoDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Giulia ToniniDermatology Unit, University of Pisa, Pisa, Italy.
Rossella MariettiDermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Gabriele CasciolaDermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Giuseppe ArgenzianoDermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Katharina HanselDermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
AtopyReg® study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveAtopyReg

methodsPatients were selected based on the following inclusion criteria: age ≥ 18 years; Eczema Area and Severity Index score ≥ 16 or localization in visible or sensitive areas (face, neck, hands, or genitalia), or a Numeric Rating Scale itch score ≥ 7 or a Numeric Rating Scale sleep loss score ≥ 7, or a Dermatology Life Quality Index score ≥ 10. Demographic and clinical data at baseline were recorded and analyzed.

resultsA total of 1170 patients (male 51.1%; mean age: 44.7 years; range 18-90 years) were enrolled by 12 Italian Dermatology Units between January 2019 and November 2022. Skin lesions were eczematous in 83.2% of patients, the most involved site were the flexures (53.9%), face (50.9%), and neck (48.0%). Mean Eczema Area and Severity Index score was 22.3, mean Dermatology Life Quality Index value was 17.6, mean Patient Oriented Eczema Measure score was 13.1, and mean Numeric Rating Scale itch and sleep loss scores were 7.6 and 5.9, respectively. Previous systemic therapies were corticosteroids in 77.7% of patients, antihistamines in 50.3% of patients, and cyclosporine A in 42.6% of patients.

conclusionsThis baseline data analysis deriving from AtopyReg

Indexed as

Dermatitis, AtopicEczemaAdolescentAdultAgedAged, 80 and overCohort StudiesFemaleHumansItalyMaleMiddle AgedProspective StudiesPruritusQuality of LifeRegistries

Identifiers

PMID37725229
PMCPMC10796485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.